Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

Chimeric antigen receptor (CAR) therapy has had a transformative effect on the treatment of
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …

Over the past decade, CRISPR has become as much a verb as it is an acronym,
transforming biomedical research and providing entirely new approaches for dissecting all …

Cell-based therapeutics are an emerging modality with the potential to treat many currently
intractable diseases through uniquely powerful modes of action. Despite notable recent …

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …

Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …

Programmable genome integration of large, diverse DNA cargo without DNA repair of
exposed DNA double-strand breaks remains an unsolved challenge in genome editing. We …